All In Biotech

Drug Trial Radar · NCT04793867

Regional Phenotyping of CF and Non-CF Bronchiectasis

Regional Phenotyping of Cystic Fibrosis Lung Disease and Non-CF Bronchiectasis

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 8, 2021

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 11, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.

Conditions

  • Cystic Fibrosis
  • Non-CF Bronchiectasis

Interventions

  • XenonDrug

    Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, "scout" images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation of ventilated volume predictions obtained with 129Xe MRI vs 1H MRITime frame: Annually for 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Penny New

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.